Quantifying molecular specificity of alphavbeta3 integrin-targeted optical contrast agents with dynamic optical imaging
Related Experiment Video
Updated: Aug 15, 2026
In vivo Imaging of Tumor Angiogenesis using Fluorescence Confocal Videomicroscopy
Published on: September 11, 2013
Michael Gurfinkel1, Shi Ke, Wei Wang
1Texas A&M University, Photon Migration Laboratories, College Station, Texas 77843-3012, USA.
Abstract:
Dynamic fluorescence images were obtained from a subcutaneous human Kaposi's sarcoma tumor (KS1767) model immediately following the intravenous injection of an integrin-targeting cyanine dye conjugate, Cy5.5-c(KRGDf). The fluorescence images, acquired via an intensified charge-coupled device detection system, were used in conjunction with a pharmacokinetic (PK) model to determine kinetic properties of target binding in the presence and absence of a competitive ligand, free c(KRGDf). The results indicate that the conjugate dye behaves similarly in normal tissue to the free Cy5.5 dye while it possesses increased uptake in tumor tissue. The change in pharmacokinetic parameters obtained from dynamic imaging of Cy5.5-c(KRGDf) after administration of c(KRGDf) as a competitive ligand to the integrin receptor suggests that (i) the increased uptake of Cy5.5-c(KRGDf) is molecularly specific and that (ii) receptor turnover occurs within 24 h. In addition, PK analysis enables quantification of an in vivo c(KRGDf) binding constant attributable to integrin binding. In vivo pharmacokinetic analysis based on rapid and dynamic optical imaging may be potentially useful for evaluating the presence and turnover rate of disease markers that are potential targets of molecular medicine.
Insights
This study shows that an integrin-targeting dye (Cy5.5-c(KRGDf)) specifically accumulates in Kaposi
Area of Science:
- Molecular Imaging
- Pharmacokinetics
- Oncology
Background:
- Integrin receptors are crucial in tumor progression and metastasis.
- Targeted molecular imaging agents can enhance tumor visualization and characterization.
- Kaposi's sarcoma (KS) presents a challenge for targeted therapies due to its complex biology.
Purpose of the Study:
- To evaluate the in vivo behavior of an integrin-targeting cyanine dye conjugate, Cy5.5-c(KRGDf).
- To determine the pharmacokinetic properties and target specificity of Cy5.5-c(KRGDf) in a Kaposi's sarcoma model.
- To assess the potential of dynamic optical imaging for evaluating disease markers.
Main Methods:
- Dynamic fluorescence imaging of Cy5.5-c(KRGDf) in a subcutaneous human Kaposi's sarcoma (KS1767) tumor model.
- Intravenous injection of the dye conjugate and a competitive ligand (c(KRGDf)).
- Pharmacokinetic (PK) modeling to analyze dye distribution and binding kinetics.
Main Results:
- Cy5.5-c(KRGDf) showed similar behavior in normal tissue as free Cy5.5 dye but increased uptake in tumor tissue.
- Competitive ligand administration confirmed molecularly specific uptake of the conjugate in tumors.
- Pharmacokinetic analysis indicated integrin receptor turnover within 24 hours and allowed quantification of binding constants.
Conclusions:
- Cy5.5-c(KRGDf) demonstrates specific accumulation in Kaposi's sarcoma tumors.
- Dynamic optical imaging combined with PK analysis is a valuable tool for assessing molecular targets in vivo.
- This approach may aid in evaluating disease markers for molecular medicine applications.
More Related Videos
09:56Universal Hand-held Three-dimensional Optoacoustic Imaging Probe for Deep Tissue Human Angiography and Functional Preclinical Studies in Real Time
Published on: November 4, 2014
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013